Acute myeloid leukemia (AML) is a prevalent hematological malignancy that exhibits a wide
array of molecular abnormalities. Although traditional treatment modalities such as …

Improved understanding of TP53 biology and the clinicopathological features of TP53-
mutated myeloid neoplasms has led to the recognition of TP53-mutated acute myeloid …

The detection of genetic aberrations is crucial for early therapy decisions in acute myeloid
leukemia (AML) and recommended for all patients. Because genetic testing is expensive …

Deregulation of the DNA damage response (DDR) plays a critical role in the pathogenesis
and progression of many cancers. The dependency of certain cancers on DDR pathways …

PURPOSE To determine the optimal induction chemotherapy regimen for younger adults
with newly diagnosed AML without known adverse risk cytogenetics. PATIENTS AND …

Abstract Antibody‐drug conjugates (ADCs), chemotherapeutic agents conjugated to an
antibody to enhance their targeted delivery to tumors, represent a significant advancement …

Background: In the past decade, there have been significant breakthroughs in
immunotherapies for B-cell lymphoid malignancies and multiple myeloma, but progress has …

Abstract Purpose: Comprehensive pharmacogenomics (PGx) evaluation of calicheamicin
pathway to identify predictive PGx markers of response to gemtuzumab ozogamicin (GO) …

Antibody-drug conjugates (ADCs) have arisen as a promising class of biotherapeutics for
targeted cancer treatment, combining the specificity of monoclonal antibodies with the …

Despite an increasing desire to use historical cohorts as “synthetic” controls for new drug
evaluation, limited data exist regarding the comparability of real-world outcomes to those in …